Wednesday in Silver Spring

tb-500 got an 8-6 compounding vote this week — the same as bpc-157

On Wednesday, July 23, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend TB-500 for inclusion on the 503A Bulk Drug Substances List — the same margin as BPC-157, which passed on the same day at the same hearing. Both votes opened a pathway for licensed compounding pharmacies to prepare and dispense these substances by name. [The FDA’s official meeting page](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) documents the full docket. The committee’s nominated indication for TB-500 was wound healing — a clinical frame that differs from the tendon repair, soft-tissue recovery, and training-injury claims that define its commercial identity. [Thomson Reuters reported the vote count the same day](https://wmbdradio.com/2026/07/23/fda-advisory-panel-votes-to-place-popular-peptide-tb-500-on-compounding-list/). As happened with BPC-157, the FDA’s own career scientists had recommended against all seven peptides at the hearing, citing insufficient human safety and efficacy data. The panel overruled that recommendation. The vote is non-binding. The FDA retains final authority, and the formal rulemaking that actually changes pharmacy access takes many additional months beyond any advisory committee recommendation.

The actual peptide

tb-500 is described as a thymosin beta-4 fragment — the distinction matters

Thymosin beta-4 is an endogenous 43-amino-acid peptide the human body produces — present in nearly every tissue, involved in actin regulation, cell motility, and wound-response signaling. That biology is real and has attracted legitimate academic research in wound healing, corneal repair, tissue remodeling, and cardiac applications. TB-500 is typically described as Ac-LKKTETQ, a synthetic peptide corresponding to the active actin-binding region of the thymosin beta-4 sequence — a fragment of the parent molecule. The commercial framing treats this fragment as functionally equivalent to thymosin beta-4, and the recovery market uses both names interchangeably. They are not the same compound. A fragment of a protein and the full protein have different pharmacokinetics, half-lives, and receptor interactions. What the fragment does independently of the full molecule is a separate scientific question from what thymosin beta-4 does. The [PubMed literature for TB-500 and thymosin beta-4](https://pubmed.ncbi.nlm.nih.gov/?term=TB-500+thymosin+beta-4) makes the research context visible: most published work is on the endogenous peptide, not on the Ac-LKKTETQ fragment sold commercially as TB-500.

The recovery pitch

the market wants tb-500 for tendon repair — the fda committee evaluated something else

The fitness and recovery community built a clear TB-500 narrative well before any FDA panel reviewed it. The pitch centers on soft-tissue repair: tendon and ligament healing, reduction of training-related inflammation, faster return from acute injuries, improved joint mobility. It often runs alongside BPC-157 in recovery stacks, where both are treated as complementary tools for the same purpose. The FDA committee this week evaluated TB-500 specifically under wound healing as its nominated indication — a clinical context that is different from the optimization and athletic-recovery framing that drives most of the market demand. The briefing materials the committee reviewed drew on thymosin beta-4 biology and the general wound-healing literature, not on controlled trials of TB-500 in active athletic populations recovering from soft-tissue injuries. This mirrors the same structure in Wednesday’s BPC-157 vote, where the committee reviewed an ulcerative colitis indication while the recovery market wanted a tendon answer. [The July 25 Peptide Dossier recap of the PCAC votes](https://peptidedossier.com/guides/pcac-hearing-bpc-157-tb-500/) shows how each peptide’s nominated indication mapped against its commercial footprint. The gap between what was on the docket and what the market buys it for is not a technical footnote — it is the entire question the compounding vote did not answer.

What the data shows

the preclinical literature is about thymosin beta-4 — not about the fragment in the vials

TB-500 holds the Anecdotal evidence tier, which sits below Animal / preclinical. That distinction is meaningful: the preclinical literature relevant to thymosin beta-4 is real and published by credible academic researchers, but the overwhelming majority of those papers study thymosin beta-4 itself, not the Ac-LKKTETQ fragment. [The PubMed literature trail for thymosin beta-4](https://pubmed.ncbi.nlm.nih.gov/?term=thymosin+beta-4+wound+healing) includes controlled animal models of wound repair, cardiac ischemia, and tissue remodeling that are mechanistically interesting. Whether those outcomes transfer to the fragment product requires separate investigation that has not been published at scale. The most advanced clinical work on a thymosin beta-4 analog in humans is RGN-352, a drug candidate developed separately and studied in specific cardiac and ophthalmology contexts — a distinct molecule, not TB-500 as sold. Human evidence for the tendon, soft-tissue, and training-recovery claims specific to TB-500 is sparse and does not establish the certainty the recovery market has assigned to it. [The FDA’s bulk drug substances guidance](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) describes the threshold the committee was applying on Wednesday — a lower bar than drug approval, not a substitute for the outcome trials that would establish soft-tissue claims directly.

Anecdotal — PeptideFactCheck stance

popular does not mean proven — and wednesday’s vote didn’t change what the evidence says

TB-500 carries the Anecdotal evidence tier, and this week’s 8-6 vote does not update that assessment. Popular does not mean proven — that is the register this tier is built to describe. The compound circulates in recovery communities with a confidence that substantially outpaces both product-specific research and the endogenous biology it borrows from. What changed this week is the regulatory pathway: licensed compounding pharmacies may eventually have a cleaner legal route to prepare and dispense TB-500 by name, under the wound-healing indication the committee reviewed. That access change is not a safety or efficacy finding. It generates no new clinical trial data. The FDA’s own career scientists opposed the recommendation precisely because the evidence base does not meet the rigor the agency’s own scientific staff considers adequate for the 503A threshold — and for TB-500, where the most relevant preclinical literature belongs to a different molecule, that shortfall is sharper than it is for compounds with a direct animal-study record. The recovery claims that drive the market for TB-500 were not evaluated on July 23. They remain unanswered by anything in the current published record.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.